The company’s ARA already bears FDA GRAS affirmation in the United States.
Under its infant formula directive, the European Commission has authorized Cargill’s (Minneapolis) arachidonic acid (ARA) fatty acid as a novel food for use in infant formula and formulas for older children. The company’s ARA already bears FDA GRAS affirmation in the United States.
ARA is an omega-6 long-chain polyunsaturated fatty acid that is a natural component of milk in human mothers. According to Cargill, ARA is included in most infant formulas on the market, promoting infant brain and vision development and often included in conjunction with DHA omega-3 fatty acid, at an approximate ARA:DHA ratio of 2:1.
Cargill greatly increased its ARA capacity in 2010 when it opened an ARA facility in Gedian, China, in partnership with Cargill Alking Bioengineering.
“Cargill is pleased that we now have the opportunity to help our European customers develop premium infant formulas using Cargill’s ARA,” said David Henstrom, Cargill Health & Nutrition’s vice president, in a press release.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.